Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity.

Li R, Kim D, Wheeler HE, Dudek SM, Dolan ME, Ritchie MD.

Pharmacogenomics J. 2018 May 25. doi: 10.1038/s41397-018-0024-6. [Epub ahead of print]

PMID:
29795408
2.

Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma.

Gamazon ER, Trendowski MR, Wen Y, Wing C, Delaney SM, Huh W, Wong S, Cox NJ, Dolan ME.

Sci Rep. 2018 Jan 15;8(1):733. doi: 10.1038/s41598-017-19004-3.

3.

Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.

Press DJ, Ibraheem A, Dolan ME, Goss KH, Conzen S, Huo D.

Breast Cancer Res Treat. 2018 Feb;168(1):207-220. doi: 10.1007/s10549-017-4587-8. Epub 2017 Nov 27.

PMID:
29181717
4.

Corrigendum: High-throughput discovery of novel developmental phenotypes.

Dickinson ME, Flenniken AM, Ji X, Teboul L, Wong MD, White JK, Meehan TF, Weninger WJ, Westerberg H, Adissu H, Baker CN, Bower L, Brown JM, Caddle LB, Chiani F, Clary D, Cleak J, Daly MJ, Denegre JM, Doe B, Dolan ME, Edie Helmut Fuchs SM, Gailus-Durner V, Galli A, Gambadoro A, Gallegos J, Guo S, Horner NR, Hsu CW, Johnson SJ, Kalaga S, Keith LC, Lanoue L, Lawson TN, Lek M, Mark M, Marschall S, Mason J, McElwee ML, Nutter SNLMJ, Peterson KA, Ramirez-Solis R, Rowland DJ, Ryder E, Samocha KE, Seavitt JR, Selloum M, Szoke-Kovacs Z, Tamura M, Trainor AG, Tudose I, Wakana S, Warren J, Wendling O, West DB, Wong L, Yoshiki A; International Mouse Phenotyping Consortium, Wurst W, MacArthur DG, Tocchini-Valentini GP, Gao X, Flicek P, Bradley A, Skarnes WC, Justice MJ, Parkinson HE, Moore M, Wells S, Braun RE, Svenson KL, de Angelis MH, Herault Y, Mohun T, Mallon AM, Henkelman RM, Brown SDM, Adams DJ, Lloyd KCK, McKerlie C, Beaudet AL, Murray MBSA.

Nature. 2017 Nov 16;551(7680):398. doi: 10.1038/nature24643. Epub 2017 Nov 8.

5.

Identification of Novel Protein Expression Changes Following Cisplatin Treatment and Application to Combination Therapy.

Stark AL, Madian AG, Williams SW, Chen V, Wing C, Hause RJ Jr, To LA, Gill AL, Myers JL, Gorsic LK, Ciaccio MF, White KP, Jones RB, Dolan ME.

J Proteome Res. 2017 Nov 3;16(11):4227-4236. doi: 10.1021/acs.jproteome.7b00576. Epub 2017 Sep 29.

PMID:
28902521
6.

Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy.

Wing C, Komatsu M, Delaney SM, Krause M, Wheeler HE, Dolan ME.

Stem Cell Res. 2017 Jul;22:79-88. doi: 10.1016/j.scr.2017.06.006. Epub 2017 Jun 15.

7.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.

Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB; Platinum Study Group.

Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13.

PMID:
28611204
8.

Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality.

Mapes B, El Charif O, Al-Sawwaf S, Dolan ME.

Clin Cancer Res. 2017 Aug 1;23(15):4010-4019. doi: 10.1158/1078-0432.CCR-17-0429. Epub 2017 Apr 25. Review.

PMID:
28442506
9.

Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach.

Eadon MT, Hause RJ, Stark AL, Cheng YH, Wheeler HE, Burgess KS, Benson EA, Cunningham PN, Bacallao RL, Dagher PC, Skaar TC, Dolan ME.

Int J Mol Sci. 2017 Mar 18;18(3). pii: E661. doi: 10.3390/ijms18030661.

10.

Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.

Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, Fossa SD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Einhorn LH, Cox NJ, Dolan ME, Travis LB.

Clin Cancer Res. 2017 Jul 1;23(13):3325-3333. doi: 10.1158/1078-0432.CCR-16-2809. Epub 2016 Dec 30.

11.

High-throughput discovery of novel developmental phenotypes.

Dickinson ME, Flenniken AM, Ji X, Teboul L, Wong MD, White JK, Meehan TF, Weninger WJ, Westerberg H, Adissu H, Baker CN, Bower L, Brown JM, Caddle LB, Chiani F, Clary D, Cleak J, Daly MJ, Denegre JM, Doe B, Dolan ME, Edie SM, Fuchs H, Gailus-Durner V, Galli A, Gambadoro A, Gallegos J, Guo S, Horner NR, Hsu CW, Johnson SJ, Kalaga S, Keith LC, Lanoue L, Lawson TN, Lek M, Mark M, Marschall S, Mason J, McElwee ML, Newbigging S, Nutter LM, Peterson KA, Ramirez-Solis R, Rowland DJ, Ryder E, Samocha KE, Seavitt JR, Selloum M, Szoke-Kovacs Z, Tamura M, Trainor AG, Tudose I, Wakana S, Warren J, Wendling O, West DB, Wong L, Yoshiki A; International Mouse Phenotyping Consortium; Jackson Laboratory; Infrastructure Nationale PHENOMIN, Institut Clinique de la Souris (ICS); Charles River Laboratories; MRC Harwell; Toronto Centre for Phenogenomics; Wellcome Trust Sanger Institute; RIKEN BioResource Center, MacArthur DG, Tocchini-Valentini GP, Gao X, Flicek P, Bradley A, Skarnes WC, Justice MJ, Parkinson HE, Moore M, Wells S, Braun RE, Svenson KL, de Angelis MH, Herault Y, Mohun T, Mallon AM, Henkelman RM, Brown SD, Adams DJ, Lloyd KC, McKerlie C, Beaudet AL, Bućan M, Murray SA.

Nature. 2016 Sep 22;537(7621):508-514. doi: 10.1038/nature19356. Epub 2016 Sep 14. Erratum in: Nature. 2017 Nov 16;551(7680):398.

12.

Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.

Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB.

J Clin Oncol. 2016 Aug 10;34(23):2712-20. doi: 10.1200/JCO.2016.66.8822. Epub 2016 Jun 27.

13.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL.

Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.

14.

Evaluation of inter-batch differences in stem-cell derived neurons.

Morrison G, Liu C, Wing C, Delaney SM, Zhang W, Dolan ME.

Stem Cell Res. 2016 Jan;16(1):140-8. doi: 10.1016/j.scr.2015.12.025. Epub 2015 Dec 31.

15.

Chemotherapy-induced peripheral neuropathy: Current status and progress.

Brewer JR, Morrison G, Dolan ME, Fleming GF.

Gynecol Oncol. 2016 Jan;140(1):176-83. doi: 10.1016/j.ygyno.2015.11.011. Epub 2015 Nov 7. Review.

16.

Orthology for comparative genomics in the mouse genome database.

Dolan ME, Baldarelli RM, Bello SM, Ni L, McAndrews MS, Bult CJ, Kadin JA, Richardson JE, Ringwald M, Eppig JT, Blake JA.

Mamm Genome. 2015 Aug;26(7-8):305-13. doi: 10.1007/s00335-015-9588-5. Epub 2015 Jul 30. Review.

17.

Characterization of CpG sites that escape methylation on the inactive human X-chromosome.

Moen EL, Litwin E, Arnovitz S, Zhang X, Zhang W, Dolan ME, Godley LA.

Epigenetics. 2015;10(9):810-8. doi: 10.1080/15592294.2015.1069461. Epub 2015 Jul 15.

18.

Application of comparative biology in GO functional annotation: the mouse model.

Drabkin HJ, Christie KR, Dolan ME, Hill DP, Ni L, Sitnikov D, Blake JA.

Mamm Genome. 2015 Oct;26(9-10):574-83. doi: 10.1007/s00335-015-9580-0. Epub 2015 Jul 4.

19.

Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.

Komatsu M, Wheeler HE, Chung S, Low SK, Wing C, Delaney SM, Gorsic LK, Takahashi A, Kubo M, Kroetz DL, Zhang W, Nakamura Y, Dolan ME.

Clin Cancer Res. 2015 Oct 1;21(19):4337-46. doi: 10.1158/1078-0432.CCR-15-0133. Epub 2015 May 26.

20.

Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.

Calinski DM, Zhang H, Ludeman S, Dolan ME, Hollenberg PF.

Drug Metab Dispos. 2015 Jul;43(7):1084-90. doi: 10.1124/dmd.115.063628. Epub 2015 May 1.

21.

SCAN database: facilitating integrative analyses of cytosine modification and expression QTL.

Zhang W, Gamazon ER, Zhang X, Konkashbaev A, Liu C, Szilágyi KL, Dolan ME, Cox NJ.

Database (Oxford). 2015 Mar 27;2015. pii: bav025. doi: 10.1093/database/bav025. Print 2015.

22.

Capturing cancer initiating events in OncoCL, a cancer cell ontology.

Dolan ME.

AMIA Jt Summits Transl Sci Proc. 2014 Apr 7;2014:41. eCollection 2014.

23.

Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.

Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Lu X, Winick NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui CH, Dolan ME, Relling MV, Evans WE.

JAMA. 2015 Feb 24;313(8):815-23. doi: 10.1001/jama.2015.0894.

24.

Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells.

Wheeler HE, Wing C, Delaney SM, Komatsu M, Dolan ME.

PLoS One. 2015 Feb 17;10(2):e0118020. doi: 10.1371/journal.pone.0118020. eCollection 2015.

25.

Methodology for the inference of gene function from phenotype data.

Ascensao JA, Dolan ME, Hill DP, Blake JA.

BMC Bioinformatics. 2014 Dec 12;15:405. doi: 10.1186/s12859-014-0405-z.

26.

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.

Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M, Reaman GH, Scorsone K, Sung L, Dolan ME, Berg SL.

Cancer Chemother Pharmacol. 2014 Oct;74(4):831-8. doi: 10.1007/s00280-014-2535-4. Epub 2014 Aug 14.

27.

Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels.

Hause RJ, Stark AL, Antao NN, Gorsic LK, Chung SH, Brown CD, Wong SS, Gill DF, Myers JL, To LA, White KP, Dolan ME, Jones RB.

Am J Hum Genet. 2014 Aug 7;95(2):194-208. doi: 10.1016/j.ajhg.2014.07.005. Epub 2014 Jul 31.

28.

Linking the genetic architecture of cytosine modifications with human complex traits.

Zhang X, Moen EL, Liu C, Mu W, Gamazon ER, Delaney SM, Wing C, Godley LA, Dolan ME, Zhang W.

Hum Mol Genet. 2014 Nov 15;23(22):5893-905. doi: 10.1093/hmg/ddu313. Epub 2014 Jun 18.

29.

Poly-omic prediction of complex traits: OmicKriging.

Wheeler HE, Aquino-Michaels K, Gamazon ER, Trubetskoy VV, Dolan ME, Huang RS, Cox NJ, Im HK.

Genet Epidemiol. 2014 Jul;38(5):402-15. doi: 10.1002/gepi.21808. Epub 2014 May 2.

30.

Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy.

Stark AL, Hause RJ Jr, Gorsic LK, Antao NN, Wong SS, Chung SH, Gill DF, Im HK, Myers JL, White KP, Jones RB, Dolan ME.

PLoS Genet. 2014 Apr 3;10(4):e1004192. doi: 10.1371/journal.pgen.1004192. eCollection 2014 Apr.

31.

Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME; Platinum Study Group.

J Natl Cancer Inst. 2014 Mar 12;106(5). pii: dju044. doi: 10.1093/jnci/dju044. Review.

32.

Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.

Wheeler HE, González-Neira A, Pita G, de la Torre-Montero JC, Alonso R, Lopez-Fernandez LA, Alba E, Martín M, Dolan ME.

Pharmacogenet Genomics. 2014 May;24(5):231-7. doi: 10.1097/FPC.0000000000000037.

33.

The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.

Moen EL, Stark AL, Zhang W, Dolan ME, Godley LA.

Mol Cancer Ther. 2014 May;13(5):1334-44. doi: 10.1158/1535-7163.MCT-13-0924. Epub 2014 Feb 25.

34.

Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.

Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME.

Clin Pharmacol Ther. 2014 Jun;95(6):644-52. doi: 10.1038/clpt.2014.37. Epub 2014 Feb 18.

35.

EPS8 inhibition increases cisplatin sensitivity in lung cancer cells.

Gorsic LK, Stark AL, Wheeler HE, Wong SS, Im HK, Dolan ME.

PLoS One. 2013 Dec 19;8(12):e82220. doi: 10.1371/journal.pone.0082220. eCollection 2013.

36.

RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK.

Pharmacogenomics. 2013 Sep;14(12):1449-66. doi: 10.2217/pgs.13.131.

37.

Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.

Dolan ME, Maitland ML, O'Donnell PH, Nakamura Y, Cox NJ, Ratain MJ.

Pharmacogenomics. 2013 Sep;14(12):1383-7. doi: 10.2217/pgs.13.134.

38.

Cell cycle arrest in a model of colistin nephrotoxicity.

Eadon MT, Hack BK, Alexander JJ, Xu C, Dolan ME, Cunningham PN.

Physiol Genomics. 2013 Oct 1;45(19):877-88. doi: 10.1152/physiolgenomics.00076.2013. Epub 2013 Aug 6.

39.

Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits.

Moen EL, Zhang X, Mu W, Delaney SM, Wing C, McQuade J, Myers J, Godley LA, Dolan ME, Zhang W.

Genetics. 2013 Aug;194(4):987-96. doi: 10.1534/genetics.113.151381. Epub 2013 Jun 21.

40.

Genetic and epigenetic variants contributing to clofarabine cytotoxicity.

Eadon MT, Wheeler HE, Stark AL, Zhang X, Moen EL, Delaney SM, Im HK, Cunningham PN, Zhang W, Dolan ME.

Hum Mol Genet. 2013 Oct 1;22(19):4007-20. doi: 10.1093/hmg/ddt240. Epub 2013 May 29.

41.

Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?

Stark AL, Dolan ME.

Pharmacogenomics. 2013 Apr;14(5):447-50. doi: 10.2217/pgs.13.32. No abstract available.

42.

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.

Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, Raimondi S, Campana D, Crews KR, Wong SS, Welsh M, Hulur I, Gorsic L, Hartford CM, Zhang W, Cox NJ, Dolan ME.

Blood. 2013 May 23;121(21):4366-76. doi: 10.1182/blood-2012-10-464149. Epub 2013 Mar 28.

43.

MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.

Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H.

Nat Commun. 2013;4:1393. doi: 10.1038/ncomms2393.

44.

Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival.

Gamazon ER, Pinto N, Konkashbaev A, Im HK, Diskin SJ, London WB, Maris JM, Dolan ME, Cox NJ, Cohn SL.

J Natl Cancer Inst. 2013 Feb 20;105(4):302-9. doi: 10.1093/jnci/djs503. Epub 2012 Dec 14.

45.

Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.

Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL; Cancer and Leukemia Group B, Cox NJ, Dolan ME.

Clin Cancer Res. 2013 Jan 15;19(2):491-9. doi: 10.1158/1078-0432.CCR-12-2618. Epub 2012 Nov 30.

46.

Pharmacogenomics of chemotherapeutic susceptibility and toxicity.

Moen EL, Godley LA, Zhang W, Dolan ME.

Genome Med. 2012 Nov 30;4(11):90. doi: 10.1186/gm391. eCollection 2012. Review.

47.

Cancer pharmacogenomics: strategies and challenges.

Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ.

Nat Rev Genet. 2013 Jan;14(1):23-34. doi: 10.1038/nrg3352. Epub 2012 Nov 27. Review.

48.

Variants affecting exon skipping contribute to complex traits.

Lee Y, Gamazon ER, Rebman E, Lee Y, Lee S, Dolan ME, Cox NJ, Lussier YA.

PLoS Genet. 2012;8(10):e1002998. doi: 10.1371/journal.pgen.1002998. Epub 2012 Oct 25.

49.

Clinical translation of cell-based pharmacogenomic discovery.

Cox NJ, Gamazon ER, Wheeler HE, Dolan ME.

Clin Pharmacol Ther. 2012 Oct;92(4):425-7. doi: 10.1038/clpt.2012.115. Epub 2012 Aug 22. Review.

50.

Identification of novel germline polymorphisms governing capecitabine sensitivity.

O'Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, Im HK, Huang RS, Cox NJ, Dolan ME.

Cancer. 2012 Aug 15;118(16):4063-73. doi: 10.1002/cncr.26737. Epub 2012 Jan 3.

Supplemental Content

Loading ...
Support Center